Performance attributes of the LCx® HCV RNA quantitative assay

Journal of Virological Methods

Volumn 115, Issue 2, 2004, Pages 207-215

  Leckie, Gregor ^a   Schneider, George ^a   Abravaya, Klara ^a   Hoenle, Robert ^a   Johanson, Julie ^a   Lampinen, John ^a   Ofsaiof, Reuben ^a   Rundle, Lisa ^a   Shah, Shruti ^a   Frank, Andrea ^a   Toolsie, Dan ^a   Vijesurier, Roy ^a   Wang, Hong ^a   Robinson, John ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

HCV; RT PCR assay; Viral load

Indexed keywords

5' UNTRANSLATED REGION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; GENOTYPE; HEPATITIS C VIRUS; HUMAN; INTERMETHOD COMPARISON; MICROPARTICLE ENZYME IMMUNOASSAY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; SENSITIVITY AND SPECIFICITY; VIRUS DETECTION;

HEPATITIS C VIRUS;

EID: 10744220199     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2003.10.001     Document Type: Article

References (31)

1. Beld M., Sentjens R., Rebers S., Weegink C., Weel J., Sol C., Boom R. Performance of the new Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum - conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, version 2.0, assay. J. Clin. Microbiol. 40:2002;788-793.
2. Choo Q.-L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 244:1989;359-362.
3. Clarke B. Molecular virology of hepatitis C virus. J. Gen. Virol. 78:1997;2397-2410.
4. Collins M.L., Zayati C., Detmer J.J., Daly B., Kolberg J.A., Cha T.-A., Irvine B.D., Tucker J., Urdea M.S. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization standards. Anal. Biochem. 226:1995;120-129.
5. Cuthbert J.A. Hepatitis C - progress and problems. Clin. Microbiol. Rev. 7(4):1994;505-532.
6. Davis G.L., Estaban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., Shiffman M., Zeuzem S., Craxi A., Ling M.-H., Albrecht J. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339:1998;1493-1499.
7. Detmer J., Lagier R., Flynn J., Zayati C., Kolberg J., Collins M., Urdea M., Sanchez-Pescador R. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J. Clin. Microbiol. 34:1996;901-907.
8. EASL International Consensus Conference on Hepatitis C, 1999. Consensus statement. J. Hepatol., 30, 956-961.
9. Fried M.W., Shiffman M.L., Reddy R., Smith C., Marinos G., Goncales F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:2002;975-982.
10. Germer J.J., Heimgartner P.J., Ilstrup D.M., Harmsen W.S., Jenkins G.D., Patel R. Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONIOR Version 2.0 assays for quantification of hepatitis C virus RNA in serum. J. Clin. Microbiol. 40(2):2002;495-500.
11. Gretch D. Standardization of hepatitis C virus-RNA quantification - advances and unfinished business. Hepatology. 31:2000;788-789.
12. Hu H.-Y., Burczak J.D., Leckie G.W., Ray K.A., Muldoon S., Lee H.H. Analytic performance and contamination control methods of a ligase chain reaction DNA amplification assay for detection of Chlamydia trachomatis in urogenital specimens. Diagn. Microbiol. Infect. Dis. 24:1996;71-76.
13. Johanson J., Abravaya K., Caminiti W., Erickson D., Flanders R., Leckie G., Marshall E., Mullen C., Ohhashi Y., Perry R., Ricci J., Salituro J., Smith A., Tang N., Vi M., Robinson J. A new ultrasensitive assay for quantitation of HIV-1 RNA in plasma. J. Virol. Methods. 95:2001;81-92.
14. Jorgensen P.A., Neuwald P.D. Standardized hepatitis C virus RNA panels for nucleic acid testing assays. J. Clin. Virol. 20:2001;35-40.
15. Kuo G., Choo Q.-L., Alter H.J., Gitnick G.L., Rederker A.G., Purcell R.H., Miyamura T., Dienstag J.L., Alter M.J., Stevens C.E., Tegtmeier G.E., Bonino F., Colombo M., Lee W.-S., Kuo G., Berger K., Shuster J.R., Overby L.R., Bradley D.W., Houghton M. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 244:1989;362-364.
16. Lee S., Antony A., Lee N., Leibow J., Yang J.Q., Soviero S., Gutenkunst K., Rosenstraus M. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA - calibration to international units, enhanced genotype reactivity, and performance characteristics. J. Clin. Microbiol. 38(11):2000;4171-4179.
17. Lindsay K.L., Trepo C., Heintges T., Shiffman M.L., Gordon S.C., Hoefs J.C., Schiff E.R., Goodman Z.D., Laughlin M., Yao R., Albrecht J.K. A randomized, double-blind trial comparing pergylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 34:2001;395-403.
18. Manns, M.P., McHutchinson, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M.-H., Albrecht, J.K., and the International Hepatitis Interventional Therapy Group, 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965.
19. Martinot-Peignoux M., Boyer N., Le Breton V., Le Guludec G., Castelnau C., Akremi R., Marcellin P. A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C. Hepatology. 31:2000;726-729.
20. McHutchinson J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.-H., Cort S., Albrecht J. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1998;1485-1492.
21. Mellor J., Hawkins A., Simmonds P. Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays. J. Clin. Microbiol. 37:1999;2525-2532.
22. NIH Consensus Development Conference Statement, 2002. Management of hepatitis C: 2002. Available at http://consensus.nih.gov/cons/116/116cdc_intro. htm . Accessed October 28, 2002.
23. Pawlotsky J.-M. Measuring hepatitis C viremia in clinical samples - can we trust the assays? Hepatology. 26:1997;1-4.
24. Pisani G., Cristiano K., Wirz M., Bisso G.M., Gentili G. Overestimation of the hepatitis C virus RNA content of reference preparations by the Amplicor HCV Monitor test version 2.0. J. Clin. Microbiol. 40:2002;4765-4767.
25. Pawlotsky J.-M., Bouvier-Alias M., Hezode C., Darthuy F., Remire F., Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology. 32:2000;654-659.
26. Ross R.S., Viazov S.O., Hoffman S., Roggendorf M. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA. J. Clin. Lab. Anal. 15:2001;308-313.
27. Ross R.S., Viazov S.O., Sarr S., Hoffman S., Kramer A., Roggendorf M. Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J. Virol. Methods. 101:2002;159-168.
28. Saldanha J., Lelie N., Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. Vox Sang. 76:1999;149-158.
29. Saldanha J., Heath A., Leli N., Pisani G., Nubling M., Yu M. Calibration of HCV working reagents for NAT assays against the HCV international standard. Vox Sang. 78:2000;217-224.
30. Trimoulet P., Halfon P., Pohier E., Khiri H., Chene G., Fleury H. Evaluation of the versant HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum. J. Clin. Microbiol. 40:2002;2031-2036.
31. Yen-Lieberman B., Brambilla D., Jackson B., Bremer J., Coombs R., Cronin M., Herman S., Katzenstein D., Leung S., Lin H.J., Palumbo P., Rasheed S., Todd J., Vahey M., Reichelderfer P. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS clinical trials group virology laboratories. J. Clin. Microbiol. 34:1996;2695-2701.